-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
WuXi AppTec Content Team Editors
Recently, Gilead Sciences and MacroGenics announced an exclusive licensing and collaboration agreement Gilead will receive a license for the investigational anti-CD123 and CD3 bispecific antibody MGD024 developed by MacroGenics, as well as two additional bispecific research projects
.
MacroGenics is a cancer innovative therapy biopharmaceutical company focused on the development and commercialization of monoclonal antibodies and has extensive experience
in developing new therapies using its proprietary bispecific antibody development platform, DART.
MGD024 is an investigational, next-generation bispecific CD123×CD3 DART molecule that uses CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
MGD024 is designed to minimize the potentially fatal toxic cytokine release syndrome (CRS) while increasing anti-tumor activity, and its extended half-life will support intermittent dosing
.
MacroGenics will lead the ongoing Phase 1 clinical study of
MGD024.
During this time, Gilead may choose to exercise its option at a pre-defined decision time to obtain a license
for the drug.
The Phase 1 study includes a dose-escalation and an extended portion to evaluate the efficacy and safety
of MGD024 as monotherapy and other combination therapies in multiple indications.
As part of the agreement, Gilead will pay an upfront payment of $60 million to MacroGenics, and MacroGenics will be eligible for a possible target selection of up to $1.
7
billion , development, regulatory and commercial milestone payments
.
"MacroGenics' expertise in bispecific antibodies complements Gilead's pipeline strengths in immuno-oncology and our growing hematology," said Bill Grossman, Ph.
D.
, senior vice president of oncology clinical development at Gilead, "We believe MGD024 with a longer half-life has the potential to lower CRS and support intermittent dosing.
" This will be a more patient-friendly dosing modality and hopefully improve clinical outcomes
for patients with AML and MDS.
Dr.
Scott Koenig, President and CEO of MacroGenics, said, "The rapid development of the past decade has made CD123 a very promising target in the field of oncology research
.
Through the strategic collaboration with the Gilead team, we will accelerate the further development of our bispecific DART molecule MGD024 for the benefit of blood cancer patients
.
" "Reference
: [1] Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies.
Retrieved October 17, 2022, from http://ir.
macrogenics.
com/news-releases/news-release-details/gilead-and-macrogenics-announce-oncology-collaboration-develop
Disclaimer: WuXi AppTec's content team focuses on global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views
in this article.
This article is also not a treatment recommendation
.
For guidance on treatment options, go to a regular hospital
.
Recently, Gilead Sciences and MacroGenics announced an exclusive licensing and collaboration agreement Gilead will receive a license for the investigational anti-CD123 and CD3 bispecific antibody MGD024 developed by MacroGenics, as well as two additional bispecific research projects
.
MacroGenics is a cancer innovative therapy biopharmaceutical company focused on the development and commercialization of monoclonal antibodies and has extensive experience
in developing new therapies using its proprietary bispecific antibody development platform, DART.
MGD024 is an investigational, next-generation bispecific CD123×CD3 DART molecule that uses CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
MGD024 is designed to minimize the potentially fatal toxic cytokine release syndrome (CRS) while increasing anti-tumor activity, and its extended half-life will support intermittent dosing
.
MacroGenics will lead the ongoing Phase 1 clinical study of
MGD024.
During this time, Gilead may choose to exercise its option at a pre-defined decision time to obtain a license
for the drug.
The Phase 1 study includes a dose-escalation and an extended portion to evaluate the efficacy and safety
of MGD024 as monotherapy and other combination therapies in multiple indications.
As part of the agreement, Gilead will pay an upfront payment of $60 million to MacroGenics, and MacroGenics will be eligible for a possible target selection of up to $1.
7
billion , development, regulatory and commercial milestone payments
.
"MacroGenics' expertise in bispecific antibodies complements Gilead's pipeline strengths in immuno-oncology and our growing hematology," said Bill Grossman, Ph.
D.
, senior vice president of oncology clinical development at Gilead, "We believe MGD024 with a longer half-life has the potential to lower CRS and support intermittent dosing.
" This will be a more patient-friendly dosing modality and hopefully improve clinical outcomes
for patients with AML and MDS.
Dr.
Scott Koenig, President and CEO of MacroGenics, said, "The rapid development of the past decade has made CD123 a very promising target in the field of oncology research
.
Through the strategic collaboration with the Gilead team, we will accelerate the further development of our bispecific DART molecule MGD024 for the benefit of blood cancer patients
.
" "Reference
: [1] Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies.
Retrieved October 17, 2022, from http://ir.
macrogenics.
com/news-releases/news-release-details/gilead-and-macrogenics-announce-oncology-collaboration-develop
Disclaimer: WuXi AppTec's content team focuses on global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views
in this article.
This article is also not a treatment recommendation
.
For guidance on treatment options, go to a regular hospital
.
